1. Home
  2. MGIC vs ANAB Comparison

MGIC vs ANAB Comparison

Compare MGIC & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magic Software Enterprises Ltd.

MGIC

Magic Software Enterprises Ltd.

HOLD

Current Price

$17.38

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$56.34

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGIC
ANAB
Founded
1983
2005
Country
Israel
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.3B
IPO Year
2002
2015

Fundamental Metrics

Financial Performance
Metric
MGIC
ANAB
Price
$17.38
$56.34
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$18.00
$62.20
AVG Volume (30 Days)
41.1K
413.2K
Earning Date
01-01-0001
04-06-2026
Dividend Yield
3.48%
N/A
EPS Growth
N/A
15.79
EPS
N/A
N/A
Revenue
N/A
$91,280,000.00
Revenue This Year
$12.87
$135.51
Revenue Next Year
$6.23
N/A
P/E Ratio
$21.93
N/A
Revenue Growth
N/A
432.03
52 Week Low
$11.65
$14.01
52 Week High
$28.00
$57.74

Technical Indicators

Market Signals
Indicator
MGIC
ANAB
Relative Strength Index (RSI) 30.58 64.52
Support Level $15.14 $43.67
Resistance Level $21.16 $57.65
Average True Range (ATR) 0.94 3.46
MACD -0.43 0.19
Stochastic Oscillator 3.18 87.14

Price Performance

Historical Comparison
MGIC
ANAB

About MGIC Magic Software Enterprises Ltd.

Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: